Triglyceride News and Research

RSS

Triglycerides are a type of fat in the bloodstream and fat tissue. Too much of this type of fat can contribute to the hardening and narrowing of your arteries. This puts you at risk of having a heart attack or stroke. Diseases such as diabetes, obesity, kidney failure or alcoholism can cause high triglycerides. Often, high triglycerides occur along with high levels of cholesterol, another type of fat. Triglycerides are measured along with cholesterol as part of a blood test. Normal triglyceride levels are below 150. Levels above 200 are high.

ZenBio to be commercial source for popular murine 3T3-L1 cell line

ZenBio announce that they will be a commercial source for the popular murine 3T3-L1 cell line, which has been fundamental in metabolic disease research for 30 years.

10 Mar 2010

Evolving sex disparity in midlife stroke prevalence: Further study needed

When it comes to stroke prevalence, it appears that the gender gap is widening. According to a new report from a researcher at the Keck School of Medicine of the University of Southern California (USC), women between the ages of 35 and 64 are almost three times more likely to have a stroke compared to men in the same age group.

26 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

Study shows more women die of heart disease each year than men

Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.

10 Feb 2010

Obesity and type 2 diabetes in younger people can increase risk of stroke and heart attack

People who are obese and have type 2 diabetes in their 20s will be at higher risk of having a heart attack or stroke in their 40s if they do not change their lifestyle.

30 Jan 2010

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders.

28 Jan 2010

Extensive gap exists between primary care practice and obesity care

Using combined and intensive treatments and restructuring care to treat obesity like other chronic diseases may help primary care clinicians and patients better address the condition, according to a commentary and three articles published in the January 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Jan 2010

USPTO grants Cenestra Health patent relating to high-purity omega-3 fatty acid formulations

Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).

27 Jan 2010

Nordic Naturals to launch special campaign for Haiti relief fund

Nordic Naturals announced today that the company has a plan for Haiti disaster relief through an immediate donation to the American Red Cross and a promotional effort that will deliver funds for the community-focused, long-term sustainable reconstruction initiative of the capital city, Port-Au-Prince.

25 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

Besides LDL, Lp(a) can also increase risk for heart disease

LDL isn't the only "bad boy" when it comes to cholesterol. According to a new study, a lipoprotein in the bloodstream called Lp(a) — pronounced "LP little A" — can be labeled "bad cholesterol."

20 Jan 2010

Isis Pharmaceuticals adds ISIS-APOCIIIRx to its development pipeline to treat TG

Isis Pharmaceuticals, Inc. announced today that it has added a new drug, ISIS-APOCIIIRx, to its development pipeline. ISIS-APOCIIIRx provides a novel approach to treat hypertriglyceridemia, or high levels of triglycerides (TG).

12 Jan 2010

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).

11 Jan 2010

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

Obese patients loosing moderate amount of weight improve their cardiovascular health, says study

Obese patients who lost a moderate amount of weight by eating less and exercising more improved their cardiovascular health, says a study at Washington University School of Medicine in St. Louis.

14 Dec 2009

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

Whole genome analysis identifies 43 genetic loci contributing to lipoprotein metabolism

Using highly precise measurements of plasma lipoprotein concentrations determined by nuclear magnetic resonance spectroscopy (NMR), researchers led by Daniel Chasman at Brigham and Women's Hospital and Harvard Medical School in Boston, MA, the Framingham Heart Study in Framingham, and the PROCARDIS consortium in Stockholm, Sweden and Oxford, England performed genetic association analysis across the whole genome among 17,296 women of European ancestry from the Women's Genome Health Study.

21 Nov 2009

Upsher-Smith Laboratories publishes results of SLIM Study

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.

17 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009